New axSpA Criteria: Who gets left out?
Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.
Watch video →What's hot!
View all perspectives
What's Hot
What Happens when CAR-T Fails Managing Disease Recurrence
Dr. Alfred Kim discusses abstracts OP0076 and OP0333 presented at EULAR 2026.
Watch video →
‘Strong’ Treatment Predictions in Inflammatory Myositis
Dr. Janet Pope, reports on abstracts POS0264 and OP0166, presented at the 2026 EULAR meeting in London.
Watch video →
Imaging in Subclinical Psoriatic Arthritis
Dr. Antoni Chan discusses abstract OP068 presented at EULAR 2026.
Watch video →
Are we failing in the treatment of RA-ILD?
Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.
Watch video →
PsA Potpourri: Probiotics & Head-to-Head Data
Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.
Watch video →
Combination Biologics in PsA: MRI Findings from AFFINITY
Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.
Watch video →
How Many CAR-Ts Do We Need to Test Drive?
Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.
Watch video →
BMI Outranks Treatment in PsA Outcomes?
Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.
Watch video →
Dietary Interventions in PsA
Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050.
Watch video →
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
Watch video →
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London
Watch video →
Day 4 Recap: EULAR 2026
Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.
Watch video →
EULAR 2026 Recommendations: Immunization
Dr. Jiha Lee reporting from EULAR 2026 in London.
Watch video →
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
Watch video →
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
Watch video →
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read more →
Aurelie Najm AurelieRheumo
2 months ago
What if we let RA patients choose ttmt?
BACH RCT choice between Filgo / scTNFi vs. standard randomisation
55% JAKi vs 45% TNFi
Higher ttmt satisfaction 46 vs 33 p=0.012
Less ttmt switches 6 vs 15 p=0.026
Less AE reported
Better drug survival
Shared decision making is key! https://t.co/1YS0y6YUEH
Mrinalini Dey DrMiniDey
2 months ago
#OP0236: a look at the revised 2025 ASAS-SPARTAN classification criteria for axSpA from the global CLASSIC cohort. The updated criteria achieved 79.5% sensitivity & 90.4% specificity, with MRI & radiographic sacroiliitis remaining central to classification. #EULAR2026 @RheumNow https://t.co/rVIqyCmB8K
Janet Pope Janetbirdope
2 months ago
Is there a ‘window
Of opportunity’ for Rx
#GCA w #IL6i
🤞
Obtain a better response
Rx GCA #GC
#TCZ
#Upadacitinib
#MTX
Study tries to answer if effects of #tocilizumab early vs >8wks is diff
N=471, 19% new GCA
Early vs late TCZ no dif
❎No
Not RCT
POS0624 #EULAR2026 @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof
2 months ago
#EULAR2026 OP002 More encouraging news in #Sjogren. A Phase II RCT in N=30 patients with ESSDAI=>5 and/or ESSPRI=>5: Anifrolumab (IFN-IR mAb) improved CRESS response vs PBO (80% vs 30%). Impressive effect size for other endpoints too. Need definitive Phase III RCT @RheumNow https://t.co/W3GbA3gKIs
Jiha Lee JihaRheum
2 months ago
Does ASA protect against JAKi-associated VTE in #RA? Swedish data (n=26,116): No. JAKi VTE risk remained elevated vs TNFi regardless of concomitant ASA or DOAC use. NSAIDs showed a non-significant trend toward protection. @RheumNow #EULAR2026 POS0068
Dr. John Cush RheumNow
2 months ago
COMPARE Trial: CAR-T Cell Rx in 6 refractory active CCP+ RA pts (failed 4-7 prior b/tsDMARDs). After lymphodepletion w/ CTX + fludarabine, B cells depleted w/ neutropenia. Significant drops in CCP, RF, and DAS28, but at wk 12 only 50% ACR 20 response. Encouraging data but not https://t.co/txm32NkOKW
Aurelie Najm AurelieRheumo
2 months ago
And we are on!
A full house for #EULAR2026 Opening ceremony highlighting @eular_org initiatives in the field of research, education and patient empowerment and a call “better care leading to better lives” by president Xenofon Baraliakos
@RheumNow https://t.co/zTQUFcjXBI
Mrinalini Dey DrMiniDey
2 months ago
It’s that time of year again! 🎉
Delighted to once again be joining the @RheumNow faculty to bring you the highlights from #EULAR2026 in London!
@bella_mehta
@JihaRheum
@AurelieRheumo
@Janetbirdope
@Nellziade
@RHEUMarampa
@synovialjoints
@Yuz6Yusof https://t.co/WvhpYJJNUk
Aurelie Najm AurelieRheumo
2 months 1 week ago
"the further I look back, the further I can see the future"
Dennis McGonagle quoting Winston Churchill to describe his approach to understanding What is New in PsA at #EULAR2026
@eular_org @RheumNow https://t.co/ayInzzb9lO
Md Yuzaiful Md Yusof Yuz6Yusof
2 months 1 week ago
#EULAR2026 OP0125 It’s a case of “teamwork makes the dream work!” Instead of an index to capture heterogeneity in #Sjogren activity, the NECESSITY validated using data from 16 RCTs that a new composite tool, STAR has high sensitivity & specificity. Vital for use in RCTs @RheumNow https://t.co/ftx1uBP11A
The first day of EULAR 2026 in London featured the opening ceremonies, a plenary session, posters nd the first round of major oral presentations to an audience of nearly 15,000 attendees. Here are a few of my favorites from the first day.
Clinicians often come across the scenario of a patient with well-controlled spondyloarthritis where the ASDAS in the low disease activity range, CRP normalised, joints clinically quiet. However, the patient returns to the clinic still reporting significant pain. Their rheumatologist adjusts the biological, waits, returns. The pain persists.
